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Conclusions. Treatment weapons against cancer have allowed us to see long time survivors despite some genetic disorders that
leads to cancer. Studying biomolecular tumorigenic pathways in this patients may lead us to better understand the basis of
cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.170
Radiation-induced atypical meningioma 19 years after treatment of medulloblastoma controlled with fraction-
ated stereotactic radiotherapy: A case report
C. Eito Valdovinos, M. Errasti Viader, G. Asín Felipe, M. Rico Osés, M. Domínguez Domínguez
Complejo Hospitalario de Navarra, Oncología Radioterápica, Spain
I present a case of meduloblastoma diagnosed en 1990, today a long term survivor for 22 years. The patient developed an atypical
meningioma 19 years after initial treatment and once again he is disease free following surgical resection and fractionated
stereotactic radiotherapy (FSRT). This is a 32 years old male patient. In 1990, at age nine, he was found to have a heterogeneously
enhancing posterior fossa mass with hydrocephalus. Gross total resection was performed and the tumor was consistent with a
classic medulloblastoma. Postoperative chemotherapy (VCR – CCNU) and 2D craniospinal radiation (34.2Gy/19 fr) with posterior
fossa 21.6Gy/12 fr boost was administered. The patient remained tumor free until November 2008, at which time he presented
with right sided weakness and numbness. MRI showed a supratentorial extra-axial mass located parasagittal into the left parietal
lobe, consistent with meningioma. Surgical resection of the tumor was undertaken on 01/22/10 and it was histopathologicaly
diagnosed as atypical meningioma WHO G2. Three months later MRI reveal a mass of 2.5 cm×2 cm×2.3 cm within the left
parietal lobe. FSRT was selected for reirradiation and 50.4Gy was delivered in 1.8Gy fractions to the gross tumor and surgical
bed PTV with 5 ﬁxed beams IMRT. He completed radiation treatments with only mild side effects but none of severe radiation
treatment late toxicities are presents today. I would note: (1) the radiation induced tumors risk after CNS irradiation; (2) the
treatment options for this condition with particular emphasis on curative reirradiation; (3) the patient status long time after
craniospinal irradiation and (4) the need of long-term follow-up for pediatric cancers survivors.
http://dx.doi.org/10.1016/j.rpor.2013.03.171
Sister’s Mary Joseph nodule at a patient followed for epidermoïde carcinoma of the cervix and literature review
S. Mansouri, A. Naim, S. Sahraoui, Z. Bouchbika, N. Benchekroun, H. Jouhadi, N. Tawﬁq, A. Benider
Radiotherapy Oncology Center of Casablanca Morroco, Spain
Sister’s Mary Joseph nodule is a rare lesion, term is used since 1949 to indicate an umbilical coetaneous metastasis of a cancer,
most often intra-abdominal principally gastric or ovarian. It represents 30% of umbilical tumours. In 90% of cases, it is about an
adenocarcinoma. The origin of the cancer is the stomach (26%), ovary (12%), colon (10%), pancreas (7%), other localizations can
be at the origin of this umbilical metastasis: appendix, small intestine. We report case of a 63-year-old patient, operated 3 years
previously for épidermoïde carcinoma type basaloide of cervix stage IB2, without ganglions invasion, followed by a concomitant
radio chemotherapy 45Gy and a vaginal irradiation 20Gy The patient presented an umbilical nodule of 5 cm, without other lesion
en abdomen or pelvis. The surgical complete resection of the nodule allowed of conﬁrmed by anatomopathological study, the
carcinoma basaloide. The diagnosis of Sister Marie Joseph’s nodule was retained. After a resection we have complete response
at 17 months, despite the poor prognosis which Sister Marie Joseph’s nodule attests.
http://dx.doi.org/10.1016/j.rpor.2013.03.173
Squamous cell carcinoma of cervix
M. Casado, S. Guardado, N. Gascón, C. Lechuga, M. Martín, M. Pérez-Escutia, J. Pérez-Regadera
Hospital 12 de Octubre, Spain
Woman, 62 years old PPH: smoker, 20 cigarettes per day Oncological History: in 1998, after being studied by metrorrhagia and
tenesmus of three months’ duration, was diagnosed ST IIIB cervical squamous cell carcinoma. Physical examination: KI: 100
gynecological exploration: exophytic cervical mass of at least 7 cm in diameter, that bleeds at touch. VT: the lump described is
felt at the left side of the vagina down to its mid third. RE: left parametrium involvement. Oncological treatment: RTE-2D over
PTV (pelvis), isocentric, 4 ﬁelds, (2AP+2LAT) with photons of 25 MV. Dosage: 50Gy, later on, overprint PTV2 (left parametrium),
2 ﬁelds, (PA and AP) Dosage: 16Gy. DT 66Gy (5×200 cGy). Cervical overprint with endocavitary radiotherapy by means of a No.
1 convergent colpostate, bearer of 3 sources of 137 CS. Dosage 15Gy to 0.5 cm of the vaginal cuff. Concurrent with Cisplatin x
6 cycles. Treatment ends on september1998. Complete clinical response. Evolution: December 2003: elevated SCC: 3.4, CYFRA:
1.9, on the thoracic abdominal pelvic TC a 3 cm right pulmonary hilar mass was noted and affected mediastinic adenopathies,
the rest was normal. February 2004: diagnostic mediastinoscopy. PA: metastasic lymph nodes squamous cell adenocarcinoma.
Rescue treatment: RTE 3D composed of PTV1 (hiliar mass+medistinum), isocentric, 4 ﬁelds (PA, AP, OBP and OBA), with 18 MV
photons, dosage: 45Gy, overprint PTV2 (hiliar tumoral mass), 2 ﬁelds (OBP and LD), 18 MV photons, dosage 14.4Gy, DT:59.4Gy
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(5×180 cGy) concurrent with taxol-carboplatin. Treatment ends on April 2004. CURRENT STATUS: it is alive and free of cancer
disease. No pulmonary toxicity, genitourinary or gastrointestinal.
http://dx.doi.org/10.1016/j.rpor.2013.03.174
Squamous cell carcinoma of cervix
M. Martín, M. Casado, S. Guardado, A. Moreno, M. Cabeza, J. Pérez-Regadera
Hospital 12 de Octubre, Spain
Woman, 45 years old. APP: No medical or surgical history interest. Oncologic history: In July 1997 she inquires about abdomi-
nal pain and was diagnosed with stage IIIB large cell cervical cancer. Physical examination: KI: 100 gynecological pelvic tumor
4-5cm in diameter, with involvement of 2/3 of vagina. TR: normal right parametrium, with inﬁltration of 3/3 of left parametrium
. Oncologic treatment: EBRT-2D on PTV (pelvis), isocentric, 4 ﬁelds (2AP-2LAT) with 25MV photons, dose 50Gy, later on overprint
on PTV2 (left parametrium), two ﬁelds (AP-PA) Dose 16Gy. Total dose 66Gy (5×200 cGy). Cervical overprinting with intracavitary
radiotherapy by means of Delouche colpostate of No.2 divergent loaded with Cs-137 dose 15Gy. Finishing treatment in December
1997. Complete remission was achieved body CT and MTs. EVOLUTION: August 2008: Elevated levels of SCC (up 2.8) and in a
pelvic MRI, a retroperitoneal limph node measuring 21mm×18mm×33mm was observed located to the right of the cava vein
and anterior to the psoas. In December 2008 a para-aortic lymphadenectomy is performed with removal of a right adenophatic
conglomerate that measures 3.5 cm×3 cm. AP: 3 nodes with metastatic large cell squamous carcinoma of nonkeratinizing pre-
dominance consistent with a primary cervicouterine carcinoma. EBRT-3D on PTV (para-aortic), isocentric 4 ﬁelds (2AP+2LAT)
with 18MV photons. Dose 45Gy (5 cGy×180 cGy) from January 2009 to February 2009. Current status: the patient remaining
asymptomatic and disease-free. ILE (36 months).
http://dx.doi.org/10.1016/j.rpor.2013.03.175
Squamous cell carcinoma of cervix and breast cancer
M. Casado, S. Guardado, N. Gascón, S. Rodríguez, Á. Moreno, M. Pérez-Escutia, J. Pérez-Regadera
Hospital 12 de Octubre, Spain
Woman, 52 years old. Oncologic history: in October 1997 she is diagnosed with a stage IIIB cervical cancer, grade III. ONCO-
LOGIC TREATMENT: EBRT-2D on PTV (pelvis) isocentric, 4 ﬁelds (2 AP+2 LAT) with 25MV photons. Dose 50Gy, later on overprint
PTV2 (right parametrium), 2 ﬁelds (AP-PA) Dose: 16Gy. TD: 66Gy (5×200 cGy). Cervical overprinting with intracavitary radio-
therapy by means of Delouche colpostate of No. 2 convergent loaded with 3 sources of Cs-137.Dose: 15Gy 0.5 of vaginal cuff.
Concurrent chemotherapy with cisplatin×6 cycles. Treatment ends in January 1998 with complete response in TAC TAP and
MTs EVOLUTION: April/2000: breast lump 1cm×0.5 cm in SEC of left breast intervened by quadrantectomy+ lymphadenectomy.
PA: inﬁltrating ductal carcinoma. pT1b No Mo. limph nodes 0/16. RE+, RP−, Herb2+. EBRT-3D on PTV (left breast), 4 ﬁelds (2 IT
and 2 ET) with 4MV photons. Total dose: 50Gy (5×200). Treatment ends August 2000. March/2001: SCC has increased and on
physical examination a 2.5 cm×1.5 cm×2 cm nodule is palpable in the left supra-clavicular fossa. PA: epidermoid metastasis.
EBRT on PTV (left supra-clavicular fossa) with 6 and 18 MV, total dose: 46Gy; then overprint to 66Gy (5×200 cGy). Was associated
Tegafur. Treatment ends June 2001 with complete clinical response (adenopathy and SCC) February/2002: SCC has increased and
abdominopelvic MRI shows paraaortic recurrence. EBRT-3D on PTV (paraaortic lymph node chain) with 18MV photons; TD: 45Gy
and later on overprint (affected adenopathies) up to 55Gy (5×180 cGy). Concurrent with cisplatin×6 cicles. Treatment ends June
2002. CURRENT STATUS Continuous revisions in the Radiation Oncology service. She is alive and free of disease.
http://dx.doi.org/10.1016/j.rpor.2013.03.176
Surviving after ﬁve years of a brain metastases diagnostic
C. Laria Font, L. Alled Comín, J. Pérez Pausin, C. Velilla Millán, J. Valencia Julve, R. Escó Barón
Hospital Clínico Universitario Lozano Blesa, Oncología Radioterápica, Spain
Brain is the most common metastatic sites of breast cancer. Brain metastases developed 10–15% of patients with this pathol-
ogy and are associated with poor prognosis. Overexpression of HER2 is a risk factor for the development of brain metastases.
Whole brain radiotherapy (WBRT) has been historically a standard of care for those patients, which extends the survival time
to an average of 4–7 months. A marked increase in the incidence of brain metastases was observed in HER2-positive because
trastuzumab (Herceptin) molecular size limits the ability to pass through the blood–brain barrier, rendering the CNS a tumour
cell sanctuary. Case report: female 45 years old, who was diagnosed of a right breast cancer in 2003. A bilateral mastectomy and
right lymphadenectomy were practiced. The right breast showed an invasive ductal carcinoma, negative hormonal receptors and
positive HER2. Four lymph nodes were affected. She was treated with six cycles of chemotherapy (adriamycin and docetaxel)
subsequently received radiotherapy at doses 5040 cGy on breast, axilla and supraclavicular area. Two years later she had an axil-
lary recurrence; Vinorelbine and Herceptin were prescribed with armpit reirradiation (3000 cGy). In March 2008, she developed
a brain metastasis, so Herceptin in combination with gemcitabine treatment were prescribed and subsequent WBRT, treatment
